Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 427-433

  Sterrantino, Gaetana ^a   Santoro, Lucia ^a   Bartolozzi, Dario ^a   Trotta, Michele ^a   Zaccarelli, Mauro ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Boosted protease inhibitors; HIV; Nonnucleoside reverse transcriptase inhibitors; Self reported adherence; Single tablet regimen

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINED ANTIRETROVIRAL THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG COMBINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PREFERENCE; QUESTIONNAIRE; SELF REPORT; SINGLE TABLET REGIMEN; TREATMENT DURATION; VIRUS LOAD;

EID: 84871643915     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S31385     Document Type: Article

References (18)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
3. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105-110.
4. Glass TR, De Geest S, Weber R, et al. Swiss HIV cohort study correlates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2006;41:385-392.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
6. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
7. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008;61:769-773.
8. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials. 2007;8:282-292.
9. Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50:1192-1197.
10. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther. 2004;9:291-296.
11. Bangsberg DR. A paradigm shift to prevent HIV drug resistance. PLoS Med. 2008;5(5):e111.
12. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40: 158-163.
13. Bangsberg D. Less than 95% adherence to non-nucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
14. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46:93-108.
15. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
16. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484-488.
17. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163-174.
18. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-125.